Cargando…
Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study
INTRODUCTION: We examined the long-term efficacy and safety of nivolumab, a human monoclonal antibody that inhibits interactions between the programmed cell death protein-1 receptor and its ligands (programmed death-ligand 1 and programmed death-ligand 2), in Japanese patients with malignant pleural...
Autores principales: | Fujimoto, Nobukazu, Okada, Morihito, Kijima, Takashi, Aoe, Keisuke, Kato, Terufumi, Nakagawa, Kazuhiko, Takeda, Yuichiro, Hida, Toyoaki, Kanai, Kuninobu, Hirano, Jun, Ohe, Yuichiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474205/ https://www.ncbi.nlm.nih.gov/pubmed/34589998 http://dx.doi.org/10.1016/j.jtocrr.2020.100135 |
Ejemplares similares
-
Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma
por: Nakagawa, Kazuhiko, et al.
Publicado: (2021) -
Physician requests by patients with malignant pleural mesothelioma in Japan
por: Nagamatsu, Yasuko, et al.
Publicado: (2019) -
JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma
por: Miyamoto, Yosuke, et al.
Publicado: (2021) -
Clinical Significance of Soluble CD26 in Malignant Pleural Mesothelioma
por: Fujimoto, Nobukazu, et al.
Publicado: (2014) -
Quality of life of survivors of malignant pleural mesothelioma in Japan: a cross sectional study
por: Nagamatsu, Yasuko, et al.
Publicado: (2018)